Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: A flexible-dose approach

Mauro Mauri, Massimo C. Mauri, Marina Adami, Giorgio Reggiardo, Corrivetti Giulio

Research output: Contribution to journalArticle

Abstract

This study evaluates the effectiveness of paliperidone ER in patients with symptomatic but not highly acute schizophrenia in terms of efficacy, safety, and patients' perception of their social functioning and well-being. This is a multicenter, open-label prospective study with a flexibledose approach; 133 patients were enrolled and followed for 13 weeks after switching to paliperidone ER. Outcome efficacy measures were as follows: the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression-Severity (CGI-S) scale, and the Personal and Social Performance (PSP) scale; in addition, the Subjective Well-being under Neuroleptics (SWN-20) scale, the Drug Attitude Inventory (DAI-30), and the sleep evaluation scale were used. Symptom Rating Scale (ESRS), adverse events, and subjective side effects were recorded. 118/133(88.7%) patients completed the study. The mean PANSS score decreased (88.98 ± 10.09 to 66.52 ± 16.29; P

Original languageEnglish
Pages (from-to)329-337
Number of pages9
JournalInternational Clinical Psychopharmacology
Volume30
Issue number6
DOIs
Publication statusPublished - Oct 1 2015

Keywords

  • DAI-31
  • Extended-release
  • Extrapyramidal Symptom Rating Scale
  • Flexible doses
  • Functioning
  • Paliperidone ER
  • Positive and Negative Syndrome Scale
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: A flexible-dose approach'. Together they form a unique fingerprint.

  • Cite this